文献速递慢性肾脏病血液净化与透析

尿EGF与肾脏结局及SGLT2抑制剂作用的关联

Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition.
PubMed 文献 · J Am Soc Nephrol · 2026-04-02

该研究在CANVAS、CREDENCE和DAPA-CKD试验的储存尿样中检测基线及第1年尿EGF,分析尿EGF/肌酐比值(uEGF/Cr)与复合肾脏结局及eGFR年下降的关联。结果显示,基线uEGF/Cr较高与肾脏结局风险较低相关,SGLT2i减轻了uEGF/Cr的下降,且uEGF/Cr早期升高具有独立于白蛋白尿的预后价值。

要点

  • 基线uEGF/Cr较高与复合肾脏结局风险较低独立相关,在有无糖尿病的CKD人群中结果一致。
  • SGLT2i较安慰剂减轻1年内uEGF/Cr下降,提示其可能有助于维持小管健康。
  • uEGF/Cr早期升高提供超越白蛋白尿的预后信息,可作为小管健康的生物标志物。

核心结论

  • uEGF/Cr是跨多种CKD人群的稳健、独立的小管健康与肾脏风险生物标志物。
  • SGLT2i减轻uEGF/Cr下降,早期uEGF/Cr变化提供超越白蛋白尿的预后信息。

研究设计与样本

  • 研究检测CANVAS、CREDENCE和DAPA-CKD试验参与者基线与第1年的储存尿样中EGF。
  • 采用多变量Cox回归评估uEGF/Cr与复合肾脏结局的关联,用双斜率线性混合效应模型评估与eGFR年下降的关联。
  • 用协方差分析评估SGLT2i对uEGF/Cr随时间变化的治疗效应。

主要发现

  • CANVAS和CREDENCE的2型糖尿病参与者(N=5978)中,基线uEGF/Cr每高两倍,复合肾脏结局风险比为0.87(95%CI 0.80至0.94)。
  • SGLT2i较安慰剂使1年内uEGF/Cr下降减轻6.7%(95%CI 2.5至10.8)。
  • 基线至第1年uEGF/Cr升高独立关联较低肾脏结局风险,校正1年白蛋白尿、eGFR等变化后仍存在。
  • DAPA-CKD试验(N=2450)重复分析结果相似,有无糖尿病参与者结果一致。

关键数值与推荐

  • 复合肾脏结局定义为持续≥40% eGFR下降、肾衰竭或肾脏相关死亡。
  • 主要暴露为基线及纵向uEGF/Cr,主要效应指标为风险比与1年内uEGF/Cr变化百分比。

临床怎么用

  • 可将uEGF/Cr作为评估CKD患者小管健康与肾脏风险的辅助生物标志物。
  • SGLT2i治疗期间uEGF/Cr早期升高可能提示小管修复改善及较低肾脏风险,可结合白蛋白尿解读。

局限性

  • 研究基于临床试验储存尿样的事后检测,uEGF/Cr的临床检测标准化与阈值尚未确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Lower urinary EGF levels, normalized to urinary creatinine, reflected impaired tubular health and were associated with higher kidney risk across CKD. Sodium-glucose cotransporter 2 inhibitors attenuated the decline in urinary EGF-creatinine ratio observed with placebo, supporting a role in maintaining tubular health. Early increases in urinary EGF-creatinine ratio were linked to lower kidney risk, adding prognostic value beyond albuminuria. BACKGROUND: Urinary EGF is a marker of tubular repair capacity. Lower urinary EGF-creatinine ratio (uEGF/Cr) levels associate with kidney disease progression in patients with type 2 diabetes at early stages of CKD. In these patients, sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with increased tubular EGF expression. In this study, we aimed to extend these findings to a broad CKD population with and without type 2 diabetes at various stages of CKD. METHODS: We measured EGF in stored urine samples at baseline and year 1 in participants from the Canagliflozin Cardiovascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), and Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) clinical trials. Associations of baseline and longitudinal uEGF/Cr with the composite kidney outcome (sustained ≥40% eGFR decline, kidney failure, or kidney-related death) were assessed using multivariable Cox regression, and associations with annual eGFR decline using a two-slope linear mixed-effects model. Treatment effects of SGLT2i on uEGF/Cr over time were analyzed with analysis of covariance. RESULTS: In participants with type 2 diabetes from the CANVAS and CREDENCE trials ( N =5978), higher baseline uEGF/Cr was associated with a lower risk of the composite kidney outcome (hazard ratio per two-fold higher uEGF/Cr, 0.87 [95% confidence interval, 0.80 to 0.94]). SGLT2i attenuated the decline in uEGF/Cr over 1 year compared with placebo by 6.7% (95% confidence interval, 2.5 to 10.8). Increases in uEGF/Cr from baseline to year 1 were independently associated with a lower risk of the kidney outcome, even after accounting for 1-year changes in albuminuria, eGFR, and other clinical variables. Replication analyses showed similar results in the DAPA-CKD trial ( N =2450), with consistent findings in participants with and without diabetes. CONCLUSIONS: These results extend previous findings, supporting uEGF/Cr as a robust, independent biomarker of tubular health and kidney risk across diverse CKD populations. SGLT2i attenuated uEGF/Cr decline, and early changes in uEGF/Cr provided prognostic information beyond albuminuria.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Moedt E, Koshino A, Jongs N, et al. Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition. J Am Soc Nephrol. 2026. PMID: 41926219. doi:10.1681/ASN.0000001086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。